|
| CASE REPORT |
|
| Year : 2021 | Volume
: 67
| Issue : 1 | Page : 43-45 |
Pembrolizumab-induced large duct cholangiopathy: Diagnosis and follow.up imaging
A Chatterjee1, BK Bivas2, A Gehani1, S Sen1
1 Department of Radiology and Imaging, Tata Medical Center, 14 Main Arterial Road (E.W), New Town, West Bengal, India
2 Department of Medical Oncology, Tata Medical Center, 14 Main Arterial Road (E.W), New Town, West Bengal, India
Correspondence Address:
A Chatterjee
Department of Radiology and Imaging, Tata Medical Center, 14 Main Arterial Road (E.W), New Town, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpgm.JPGM_793_20
Immune-checkpoint inhibitor mediated hepatobiliary injury is an emerging concern in cancer treatment. Most of these adverse reactions are attributed to nivolumab and are characterized by panlobular hepatitis. Large duct cholangiopathy related to these drugs is extremely rare. We present a case of adenocarcinoma of lung treated with pembrolizumab who developed biochemical and imaging features consistent with cholangiopathy characterized by common bile duct dilatation, wall enhancement, and gallbladder wall edema. On follow-up in the fourth month, the imaging features persisted despite the normalization of liver enzymes. To the best of our knowledge, this is the first description of diagnosis and follow-up imaging of pembrolizumab-related cholangiopathy in imaging literature.
[FULL TEXT] [PDF]*
|
